Myriad Genetics, Inc. (MYGN) Announces New, Convenient OnDose(TM) Sampling Kit
4/28/2010 9:14:32 AM
SALT LAKE CITY, April 27, 2010 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced a significant improvement in the sample collection kit for OnDoseTM, its 5-Fluorouracil (5-FU) dose optimization product. Patient sample handling can now be conducted at room temperature, eliminating the need for frozen sample handling. Myriad said that it believes the simplified process should increase physician acceptance and utilization of OnDose.